The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the prospective PETAML trial
| Title: | The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the prospective PETAML trial |
|---|---|
| Authors: | Friedrich Stölzel, Tors Lüer, Steffen Löck, Stefani Parmentier, Friederike Kuithan, Michael Kramer, Nael S. Alakel, Katja Sockel, Franziska Taube, Jan M. Middeke, Johannes Schetelig, Christoph Röllig, Tobias Paulus, Jörg Kotzerke, Gerhard Ehninger, Martin Bornhäuser, Markus Schaich, Klaus Zoephel |
| Source: | Haematologica, Vol 105, Iss 6 (2020) |
| Publisher Information: | Ferrata Storti Foundation, 2020. |
| Publication Year: | 2020 |
| Collection: | LCC:Diseases of the blood and blood-forming organs |
| Subject Terms: | Diseases of the blood and blood-forming organs, RC633-647.5 |
| More Details: | Extramedullary (EM) disease in patients with acute myeloid leukemia (AML) is a known phenomenon. Since the prevalence of EM AML has so far only been clinically determined on examination, we performed a prospective study in patients with AML. The aim of the study was to determine the prevalence of metabolically active EM AML using total body 18Fluorodesoxy-glucose positron emission tomography/computed tomography (18FDG-PET/CT) imaging at diagnosis prior to initiation of therapy. In order to define the dynamics of EM AML throughout treatment, PET-positive patients underwent a second 18FDG-PET/CT imaging series during follow up by the time of remission assessment. A total of 93 patients with AML underwent 18FDG-PET/CT scans at diagnosis. The prevalence of PET-positive EM AML was 19% with a total of 65 EM AML manifestations and a median number of two EM manifestations per patient (range, 1-12), with a median maximum standardized uptake value of 6.1 (range, 2-51.4). When adding those three patients with histologically confirmed EM AML who were 18FDG-PET/CT negative in the 18FDG-PET/CT at diagnosis, the combined prevalence for EM AML was 22%, resulting in 77% sensitivity and 97% specificity. Importantly, 60% (6 of 10) patients with histologically confirmed EM AML still had active EM disease in their follow up 18FDG-PET/CT. 18FDG-PET/CT reveals a high prevalence of metabolically active EM disease in AML patients. Metabolic activity in EM AML may persist even beyond the time point of hematologic remission, a finding that merits further prospective investigation to explore its prognostic relevance. (Trial registered at clinicaltrials.gov identifier: 01278069.) |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 0390-6078 1592-8721 |
| Relation: | https://haematologica.org/article/view/9430; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721 |
| DOI: | 10.3324/haematol.2019.223032 |
| Access URL: | https://doaj.org/article/5d4ebb602d894bf69e83fff1213f1bd8 |
| Accession Number: | edsdoj.5d4ebb602d894bf69e83fff1213f1bd8 |
| Database: | Directory of Open Access Journals |
| ISSN: | 03906078 15928721 |
|---|---|
| DOI: | 10.3324/haematol.2019.223032 |
| Published in: | Haematologica |
| Language: | English |